PBH Stock Forecast & Price Target

Prestige Consumer Healthcare is well-positioned for growth, demonstrated by the upward revision of EBITDA estimates for 2026 and 2027 by approximately $15 million due to increased sales projections. The company anticipates an acceleration in organic volume growth rate in the second half of 2025, supported by significant new product launches and improved operating performance, particularly in North America where 85% of revenues are generated. Additionally, strong revenue growth forecasts of approximately 18.5% year-over-year for Specialty Foods in Q3/25, alongside positive same-store sales trends in both the U.S. and Canada, further enhance the positive outlook for Prestige Consumer's stock.

Prestige Consumer Healthcare faces significant challenges that contribute to a negative outlook on its stock. Key concerns include lower-than-expected revenue growth and ongoing EBITDA margin compression due to persistent increases in input costs, which could continue to pressure profitability. Additionally, risks such as a softer operating environment in core markets and potential difficulties in acquisition opportunities further compound the uncertainty surrounding the company’s financial stability and future performance.